New Exacerbation Data Improves Prospects For AstraZeneca’s Airsupra

The Avillion-partnered treatment has succeeded in the BATURA trial, adding to the body of evidence supporting Airsupra as a first-in-class rescue treatment and its role in reducing the risk of asthma exacerbations in patients regardless of disease severity.

Neon Light Sign Lungs Icon
• Source: Shutterstock

AstraZeneca PLC and fellow UK partner Avillion LLP's bid to expand the market for Airsupra has been boosted by "overwhelming" data from a study halted early after the their first-in-class asthma rescue inhaler outperformed the decades-old standard of care.

The firms have presented positive top-level results from the BATURA Phase IIIb trial which showed that Airsupra, a fixed-dose combination...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Respiratory

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By 

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.